A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis

By sjmartinez • October 22, 2022

Tayek JA, Stolz AA, Nguyen DV, Fleischman MW, Donovan JA, Alcorn JM, Chao DC, Asghar A, Morgan TR; Southern California Alcoholic Hepatitis (SCAH) Consortium. A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis. EClinicalMedicine. 2022 Oct 12;54:101689. doi: 10.1016/j.eclinm.2022.101689. PMID: 36267499; PMCID: PMC9576807.

Tags: ACLF, acute kidney injury, acute on chronic liver failure, AH, AKI, alcohol-related hepatitis, Alcoholic hepatitis, common terminology criteria for adverse events, CTCAE, data safety monitoring board, DF, discriminant function, DSMB, FDA, follow-up, food and drug administration, FU, GCSF, General Internal Medicine, granulocyte colony stimulating factor, Harbor UCLA, hepatorenal syndrome, HIV, HRS, human immunodeficiency virus, INR, international normalized ratio, national institute on alcohol abuse and alcoholism, NIAAA, Pegfilgrastim, Phase II, Publications, Randomized clinical trial, SD, SOC, standard deviation, standard of care, WBC, white blood cell count

Breaking the Chain of Survival: What Progetto Vita Tells Us, and What It Doesn’t

Talishinsky A, Ajijola OA, Salhi RA. Breaking the Chain of Survival: What Progetto Vita Tells Us, and What It Doesn't. J Am Heart Assoc. 2025[...]

Longitudinal Trajectories of Multimorbidity and Psychosocial Resilience Resources in Midlife and Older Adults: Findings From the Health and Retirement Study

White Whilby K, Robinson-Ector K, Bell BA, Ma T, Hasan S, Quiñones AR, Wei MY. Longitudinal Trajectories of Multimorbidity and Psychosocial Resilience Resources in Midlife[...]

Applying Race and Ethnicity in Health Disparities Research

Norris KC, Hudson MF, Wilson MR, Wojcik GL, Ofili EO, Hedges JR. Applying Race and Ethnicity in Health Disparities Research. Int J Environ Res Public[...]